OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Diabetes & Endocrinology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	1003
World Health Assembly ratifies first global diabetes targets	695
Mark Atkinson: bringing two worlds together	607
What's preventing us from curbing the obesity crisis?	593
Direct-to-consumer services: improving access to care for people with diabetes and obesity	440
Better testing and labelling of drugs for people with obesity	436
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	432
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	420
Artificial intelligence and diabetes: time for action and caution	397
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	361
South Africa to produce insulin for Africa in 2024	360
Anand Hardikar: a scientific nomad searching for the truth	331
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	286
Reassessing driving safety in diabetes	275
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	264
A framework for improving diabetes care in humanitarian emergencies	218
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	218
Implications of technology guidelines for low-income and middle-income countries	210
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	208
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	195
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	194
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	193
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	179
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	166
Obesity in people living with type 1 diabetes	161

Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	154
Nutritional intake and bone health	147
Jennifer Manne-Goehler: at the crossroads of pandemics	146
The uncomfortable truth about kidney disease in type 1 diabetes	138
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	137
A roadmap for integrating mental health and diabetes services	137
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	136
Dapagliflozin in patients with COVID-19: truth or dare	135
Putting wellbeing at the core of diabetes care	134
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	127
Glycaemic index as part of the diabetes prevention strategy	125
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	124
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	119
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	119
Principles for virtual health care to deliver real equity in diabetes	118
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	118
Lebanon: insulin out of reach after subsidies lifted	118
What does renal failure teach us about our National Health System?	116
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	110
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	102
The role of nurses in diabetes care: challenges and opportunities	102
Rising diabetes diagnosis in long COVID	100
Challenging diabetes stigma starts and ends with all of us	99
Healthy weight for the next generation's health in China	98
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial	98
The promise and hope of GLP-1 receptor agonists	97
The changing character of diabetes complications	97
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	93
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	90
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	88
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	87
Childhood obesity: a growing pandemic	87
Women in diabetes research: stepping towards equity	81
Is it time to re-assess the development of thyroid function reference ranges?	80
Blood pressure control according to type 2 diabetes status	73
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	72
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	71
Homing in on the causes of male infertility	68
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	68
Male hypogonadism: pathogenesis, diagnosis, and management	67
CONCEPTT to care: the science of implementation in diabetes care	66
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	65
Gender equality: timely and timeless	64
Diabetes: knowing your risk matters	64
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	64
Improving HbA1c levels with advanced hybrid closed-loop therapy	63
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	63
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	63
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	63
Hypothalamic obesity: from basic mechanisms to clinical perspectives	62

Glucagon, from past to present: a century of intensive research and controversies	61
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	61
On the occasion of International Women's Day	60
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	60
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	60
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes	59
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	58
Central diabetes insipidus from a patient's perspective	58
Vanita Aroda: the accidental role model… by no accident	58
Chronicling insulin from discovery to crisis	57
Embracing community sport to promote global health	56
Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28	56
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	56
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	55
Vitamin D and fractures	55
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	55
Improving support for university students with type 1 diabetes	54
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	53
Teplizumab approval for type 1 diabetes in the USA	53
Health disparities in transgender people	52
Screening type 1 diabetes and celiac disease by law	52
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	52
Management of menopause: a view towards prevention	51
Diagnosing diabetes in African populations: a twist in the tale	51
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	49
Methodological considerations in D-health cancer mortality results – Authors' reply	48
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia	48
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	47
Technology for type 1 diabetes: what impact will it have?	47
Young adult-onset type 2 diabetes heralds a poor prognosis	47
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	47
Automated insulin delivery postpartum: insights from the AiDAPT study extension	47
How do clinicians integrate oral octreotide into their treatment plan for acromegaly?	47
Insulin regimens during type 1 diabetes pregnancy	47
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	46
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	46
More options for young children with type 1 diabetes	46
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	45
Blood glucose targets in the critically ill: is one size fits all still appropriate?	45
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	44
Is the impact of add on heart failure therapy influenced by background therapy?	44
RETRACTED: Targeting of vitamin D supplementation to individuals with deficiency	44
Viswanathan Mohan: a dynasty of diabetology	44
MarÍa José Redondo: rethinking type 1 diabetes	43
Enhancing global access to diabetes medicines: policy lessons from the HIV response	43
Creating diabetes guidelines for the individual not just the illness	43
ORION-3: delivering lipid lowering treatment for longer	42
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	42
Disparities in fragility fracture and osteoporosis care in Africa	41
How clinically relevant is statin-induced diabetes?	41
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	41
Primum non nocere—first, do no harm with bariatric surgery	40
Impact of higher BMI on cardiometabolic risk: does height matter?	40
An inclusive approach to people with disabilities in diabetes care and education	40
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	39
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	38
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	38
Addressing health and demographic challenges in Japan's ageing society	38
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	38
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	37
Redefining obesity: advancing care for better lives	37
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	37
Risks and burdens of incident diabetes in long COVID: a cohort study	36
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	36
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	35
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials	35
What's in a decade?	34
Data processing in the DMagic cluster randomised controlled trial	33
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	33
Gender disparities in publishing: from words to actions	33
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era	32
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	32
The growing global burden of thyroid cancer overdiagnosis	32
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	31
Disease modifying therapies in diabetes and endocrinology	31
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	30
Mendelian randomisation and vitamin D: the importance of model assumptions	30
Setmelanotide: new promise for the treatment of hypothalamic obesity?	30
From prominent corneal nerves to multiple endocrine neoplasia type 2B	29
Diabetes and the WHO Model List of Essential Medicines	29

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	29
Sleep: a neglected public health issue	29
Incretins and the cardiovascular system: bridging digestion with metabolism	29
The potential role for artificial intelligence in fracture risk prediction	28
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	28
Iodine deficiency in Europe: vigilance and action required	28
Sex differences in familial hypercholesterolaemia	27
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	27
The double burden of poor diets	27
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	27
Osteoporosis in men	27
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	26
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	26
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	25
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	25
Revisiting osteoporosis guidelines	25
Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care	25
Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study	25
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	23
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	23
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	23
Maternal thyroid hypofunction and gestational diabetes risk	23
Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records	23
The power of resilience	23
From research to policy: still a long way to go	22
A global plastics treaty to protect endocrine health	22
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	22
Bariatric surgery in children with obesity and type 2 diabetes	22
PFAS: here today—here tomorrow	22
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	21
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	21
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	21
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	21
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	21
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	20
Endocrine health in survivors of adult-onset cancer	20
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	20
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	20
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	20
Sexual dimorphism in COVID-19: potential clinical and public health implications	20
Statins for Graves' orbitopathy: a new tool for prevention and treatment?	19
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	18
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	18
The voices of lived experience in diabetes and endocrinology	17
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	17
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	17
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	17
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	17
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	17
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	17
Predicting and preventing heart failure in type 2 diabetes	17
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	16
Does tirzepatide treatment improve skeletal muscle composition?	16
COVID-19 targets human adrenal glands	16
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	15
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	15
Is autonomous cortisol secretion sexually dimorphic?	15
The ISPAD Clinical Practice Consensus Guidelines 2022: how far we have come and the distance still to go	15
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium	15
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	15
Type 1 diabetes: one size does not fit all	15
Diabetes educators: rewriting the narrative	15
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	15
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention	15
Denosumab in the treatment of osteoporosis associated with chronic kidney disease	15
The actual burden of obesity—accounting for multimorbidity	14
Correction to Lancet Diabetes Endocrinol 2023; 11: 567–77	14
Endpoints for clinical trials in type 1 diabetes drug development	14
Vitamin D and acute respiratory infections: a definitive answer?	14
Food additive emulsifiers and risk of type 2 diabetes	14
Migrant health: a global responsibility	14
The obesity drug craze in Brazil	14
The evidence for achondroplasia in 1st century AD Italy	14
Access to insulin and diabetes care in the Philippines	14
Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial	13
Alarming rise in young-onset type 2 diabetes	13
Polycystic ovary syndrome	12
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, paralle	12
Obesity in Qatar: current and future strategies	12
Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment	12
Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity	12
Heart failure: now centre-stage in diabetes	12
Causes, prevention, and management of diabetes-related foot ulcers	12
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada	12
Osteoporosis in the USA: prevention and unmet needs	12
Carmella Evans-Molina: being of service	11
The enduring effect of the COVID-19 pandemic on diabetes	11
Diabetes in humanitarian crises	11
Prequalification of insulin: what is missing?	11
Effect of COVID-19 restrictions on thyroid cytopathology: delay in the diagnosis of indeterminate lesions	11
Diabetes education: the key to a brighter tomorrow	11
Answering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries	11
Melatonin: is it really a cardiovascular wonder pill for shift workers?	11
Diabetes and frailty in an ageing world	10
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial	10